8 research outputs found
Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΠΈ Π² ΡΠΎΠ·Π΄Π°Π½ΠΈΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΠ»ΡΡΠ³Π΅ΠΉΠΌΠ΅ΡΠ° ΠΈ ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΠΏΡΡΠ°Π½ΠΈΡ
Intracellular and extracellular accumulation of fibrillary proteins, beta-amyloid and hyperphosphorylated Tau, in patients with Alzheimerβs disease (AD) leads to chronic and progressive neurodegenerative process. Overaccumulation of aggregates results in synaptic dysfunction and inevitable neuronal loss. Although the exact molecular pathways of the AD still require better understanding, it is clear this neuropathology is a multifactorial disorder where the advanced age is the main risk factor. Lately, several dozens of drug candidates have succeeded to phase II clinical trials; however, none has passed phase III. In this review we summarize existing data on anti-AD therapeutic agents currently undergoing clinical trials and included in the public websites www.clinicaltrials.gov and Alzforum.org as well as the Thomson Reuters Β«IntegrityΒ» database. We revealed three major trends in AD drug discovery. First, developing of βdisease-modifying agentsβ could potentially slow the progression of structural and functional abnormalities in the central nervous system providing sustainable improvements of cognitive functions, which persist even after drug withdrawal. Secondly, the focused design of multitargeted drugs acting on multiple key molecular pathways. Finally, the repositioning of drugs that are already available on the market for the novel (anti-AD) application provides a promising strategy for finishing clinical trials and re-marketing.ΠΡΠΈ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΠ»ΡΡΠ³Π΅ΠΉΠΌΠ΅ΡΠ° (ΠΠ) ΠΏΡΠΎΠΈΡΡ
ΠΎΠ΄ΠΈΡ Π²Π½ΡΡΡΠΈΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ΅ ΠΈ Π²Π½Π΅ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ΅ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΠ΅ ΡΠΈΠ±ΡΠΈΠ»Π»ΡΡΠ½ΡΡ
Π±Π΅Π»ΠΊΠΎΠ²: Π±Π΅ΡΠ°-Π°ΠΌΠΈΠ»ΠΎΠΈΠ΄Π° ΠΈ Π³ΠΈΠΏΠ΅ΡΡΠΎΡΡΠΎΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΠ°Ρ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡ ΠΊ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌΡ ΠΈ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΡΡΡΠ΅ΠΌΡ Π½Π΅ΠΉΡΠΎΠ΄Π΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠΌΡ ΠΏΡΠΎΡΠ΅ΡΡΡ Π² ΠΌΠΎΠ·Π³Π΅. ΠΠ°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΠ΅ ΠΎΡΠ»ΠΎΠΆΠ΅Π½ΠΈΠΉ Π²ΡΠ·ΡΠ²Π°Π΅Ρ ΡΠΈΠ½Π°ΠΏΡΠΈΡΠ΅ΡΠΊΡΡ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΡ ΠΈ Π½Π΅ΠΈΠ·Π±Π΅ΠΆΠ½ΡΡ Π³ΠΈΠ±Π΅Π»Ρ Π½Π΅ΠΉΡΠΎΠ½ΠΎΠ². ΠΠΎ ΡΠΈΡ
ΠΏΠΎΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ ΠΠ ΠΈΠ·ΡΡΠ΅Π½Ρ Π½Π΅ ΠΏΠΎΠ»Π½ΠΎΡΡΡΡ, ΠΎΠ΄Π½Π°ΠΊΠΎ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΠ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΌΠ½ΠΎΠ³ΠΎΡΠ°ΠΊΡΠΎΡΠ½ΡΠΌ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²ΠΎΠΌ, ΠΏΡΠΈ ΡΡΠΎΠΌ ΠΏΡΠ΅ΠΊΠ»ΠΎΠ½Π½ΡΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ ΡΠΈΡΠΊΠ°. ΠΠ° ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅Π΅ Π΄Π΅ΡΡΡΠΈΠ»Π΅ΡΠΈΠ΅ Π±ΠΎΠ»Π΅Π΅ 50 Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΠΊΠ°Π½Π΄ΠΈΠ΄Π°ΡΠΎΠ² ΡΡΠΏΠ΅ΡΠ½ΠΎ ΠΏΡΠΎΡΠ»ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ II ΡΠ°Π·Ρ, ΠΏΡΠΈ ΡΡΠΎΠΌ Π½ΠΈ ΠΎΠ΄ΠΈΠ½ ΠΈΠ· Π½ΠΈΡ
Π½Π΅ ΠΏΡΠΎΡΠ΅Π» ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ°Π·Ρ III. Π‘ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΎΠ±ΡΠ΅Π΄ΠΎΡΡΡΠΏΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠ΅ΡΠ½Π΅Ρ-ΡΠ΅ΡΡΡΡΠ° www.clinicaltrials.gov ΠΈ Alzforum.org, Π° ΡΠ°ΠΊΠΆΠ΅ Π±Π°Π·Ρ Thomson Reuters βIntegrityβ Π² ΠΎΠ±Π·ΠΎΡΠ΅ ΡΡΠΌΠΌΠΈΡΠΎΠ²Π°Π½Ρ Π΄Π°Π½Π½ΡΠ΅ ΠΏΠΎ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΠ»ΡΡΠ³Π΅ΠΉΠΌΠ΅ΡΠ°, Π½Π°Ρ
ΠΎΠ΄ΡΡΠΈΡ
ΡΡ Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π½Π° ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ
. ΠΡΠ΄Π΅Π»Π΅Π½Ρ Π½Π΅ΠΊΠΎΡΠΎΡΡΠ΅ ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΠΈ: (1) ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ, Π΄Π΅ΠΉΡΡΠ²ΡΡΡΠΈΡ
Π½Π° ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΡΡΠ°Π΄ΠΈΠΈ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π° Π±ΠΎΠ»Π΅Π·Π½ΠΈ (ΡΠ°ΠΊ Π½Π°Π·ΡΠ²Π°Π΅ΠΌΡΠ΅ βΠ±ΠΎΠ»Π΅Π·Π½Ρ-ΠΌΠΎΠ΄ΠΈΡΠΈΡΠΈΡΡΡΡΠΈΠ΅β ΡΡΠ΅Π΄ΡΡΠ²Π°) β ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΌΠΎΠ³ΡΡ Π·Π°ΠΌΠ΅Π΄Π»ΠΈΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΡΡΡΡΠΊΡΡΡΠ½ΡΡ
ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
Π°Π½ΠΎΠΌΠ°Π»ΠΈΠΉ Π² ΡΠ΅Π½ΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π½Π΅ΡΠ²Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΠ΅, ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°Ρ ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΠ΅ ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΡ
ΡΡΠ½ΠΊΡΠΈΠΉ, ΡΠΎΡ
ΡΠ°Π½ΡΡΡΠΈΡ
ΡΡ Π΄Π°ΠΆΠ΅ ΠΏΠΎΡΠ»Π΅ ΠΎΡΠΌΠ΅Π½Ρ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°; (2) ΡΠ΅Π»Π΅Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½Π°Ρ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΌΡΠ»ΡΡΠΈΡΠ°ΡΠ³Π΅ΡΠ½ΡΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ², Π΄Π΅ΠΉΡΡΠ²ΡΡΡΠΈΡ
Π½Π° Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ
ΠΌΠΈΡΠ΅Π½Π΅ΠΉ, Π²ΠΎΠ²Π»Π΅ΡΠ΅Π½Π½ΡΡ
Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π· Π±ΠΎΠ»Π΅Π·Π½ΠΈ; (3) ΡΠ΅ΠΏΠΎΠ·ΠΈΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈΠ·Π²Π΅ΡΡΠ½ΡΡ
ΡΠ°Π½Π΅Π΅ Π»Π΅ΠΊΠ°ΡΡΡΠ² Π½Π° Π½ΠΎΠ²ΠΎΠ΅ (Π°Π½ΡΠΈ-Π°Π»ΡΡΠ³Π΅ΠΉΠΌΠ΅ΡΠΎΠ²ΡΠΊΠΎΠ΅) ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅, ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΡΡΠ΅Π΅ ΡΠΎΠ±ΠΎΠΉ ΠΎΡΠ΅Π½Ρ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄
ΠΠ²ΠΎΠ»ΡΡΠΈΡ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΌΠΎΡΠΎΡΠ½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ Π³ΡΡΠ·ΡΠ½ΠΎΠ², ΠΌΠΎΠ΄Π΅Π»ΠΈΡΡΡΡΠΈΡ Π½Π΅ΠΉΡΠΎΠ΄Π΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠ²Π½ΡΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ
This review contains information about different laboratorian rodentβ²s gait analysis systems. These methods are useful for the assessment of motor function in neurodegenerative models. The following aspects have been considered: ink traces technique, treadmills equipment, and modern gait analysis systems like TreadScan and CatWalk, which allows estimating a set of animals gait parameters. For each technique a detailed description and examples of its use for estimating gait parameters in neurodegenerative diseases are given.Π Π΄Π°Π½Π½ΠΎΠΉ ΡΡΠ°ΡΡΠ΅ ΡΠ΅ΡΡ ΠΏΠΎΠΉΠ΄ΡΡ ΠΎ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ°Ρ
ΠΎΡΠ΅Π½ΠΊΠΈ ΠΏΠΎΡ
ΠΎΠ΄ΠΊΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
Π³ΡΡΠ·ΡΠ½ΠΎΠ². ΠΠ°Π½Π½ΡΠ΅ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ ΡΠ²Π»ΡΡΡΡΡ ΡΠ΅ΠΏΡΠ΅Π·Π΅Π½ΡΠ°ΡΠΈΠ²Π½ΡΠΌΠΈ Π΄Π»Ρ ΠΎΠΏΠΈΡΠ°Π½ΠΈΡ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ Π½Π΅ΠΉΡΠΎΠ΄Π΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠ²Π½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΠΏΠΎΠ²Π΅Π΄Π΅Π½ΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π½Π° ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
ΠΌΠΎΠ΄Π΅Π»ΡΡ
. Π ΡΡΠ°ΡΡΠ΅ ΠΏΠ΅ΡΠ΅ΡΠΈΡΠ»Π΅Π½Ρ ΡΠ°ΠΊΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ ΠΊΠ°ΠΊ ΡΠ΅Ρ
Π½ΠΈΠΊΠ° ΡΠ΅ΡΠ½ΠΈΠ»ΡΠ½ΡΡ
ΡΠ»Π΅Π΄ΠΎΠ², Π±Π΅Π³ΠΎΠ²ΡΠ΅ Π΄ΠΎΡΠΎΠΆΠΊΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΡΠΈΡΡΠ΅ΠΌΡ TreadScan ΠΈ CatWalk, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠΈΠ΅ ΠΎΡΠ΅Π½ΠΈΠ²Π°ΡΡ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²ΠΎ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΠΏΠΎΡ
ΠΎΠ΄ΠΊΠΈ ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
. ΠΠ»Ρ ΠΊΠ°ΠΆΠ΄ΠΎΠΉ ΠΈΠ· ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊ Π΄Π°Π½ΠΎ ΠΏΠΎΠ΄ΡΠΎΠ±Π½ΠΎΠ΅ ΠΎΠΏΠΈΡΠ°Π½ΠΈΠ΅ ΠΈ ΠΏΡΠΈΠΌΠ΅ΡΡ Π΅Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΠΏΠΎΡ
ΠΎΠ΄ΠΊΠΈ ΠΏΡΠΈ Π½Π΅ΠΉΡΠΎΠ΄Π΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠ²Π½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΡ
Gamma-carbolines derivatives as promising agents for the development of pathogenic therapy for proteinopathy
Uncontrolled protein aggregation, accompanied by the formation of specific inclusions, is a major
component of the pathogenesis of many common neurodegenerative diseases known as proteinopathies. The
intermediate products of this aggregation are toxic to neurons and may be lethal. The development strategy of
pathogenic therapy for proteinopathy is based on the design of drugs capable of both inhibiting proteinopathy
progression and increasing the survival of affected neurons. The results of a decade-long research effort at
leading Russian and international laboratories have demonstrated that Dimebon (Latrepirdine), as well as a
number of its derivatives from a gamma-carboline group, show a strong neuroprotective effect and can modulate
the course of a neurodegenerative process in both in vitro and in vivo model systems. The accumulated
data indicate that gamma-carbolines are promising compounds for the development of pathogenic therapy for
proteinopathies
Gamma-carbolines derivatives as promising agents for the development of pathogenic therapy for proteinopathy
Uncontrolled protein aggregation, accompanied by the formation of specific inclusions, is a major
component of the pathogenesis of many common neurodegenerative diseases known as proteinopathies. The
intermediate products of this aggregation are toxic to neurons and may be lethal. The development strategy of
pathogenic therapy for proteinopathy is based on the design of drugs capable of both inhibiting proteinopathy
progression and increasing the survival of affected neurons. The results of a decade-long research effort at
leading Russian and international laboratories have demonstrated that Dimebon (Latrepirdine), as well as a
number of its derivatives from a gamma-carboline group, show a strong neuroprotective effect and can modulate
the course of a neurodegenerative process in both in vitro and in vivo model systems. The accumulated
data indicate that gamma-carbolines are promising compounds for the development of pathogenic therapy for
proteinopathies
Π‘Π²Π΅ΡΡ Π²ΡΡΠΎΠΊΠΎΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΠΉ ΠΏΠΎΠ»ΠΈΡΡΠΈΠ»Π΅Π½ (Π‘ΠΠΠΠ) ΠΊΠ°ΠΊ ΠΎΡΠ½ΠΎΠ²Π° ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΡΠΈΠΊΡΠ° Π΄Π»Ρ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ 3D ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΠΊΡΠ»ΡΡΡΡΡ
The study is devoted to the development of an artificial material based on the ultrahigh-molecular weight polyethylene (UHMWPE) with a porous or cellular 3D structure as a cellular matrix β a framework for growing cell cultures. The development of such matrix provides support for neuronal cell culture under conditions that mimick those that exist in the living body. Typically, in vitro cellular studies are conducted in a 2D format, which limits intercellular interactions, morphology, differentiation, survival, signaling responses, gene expression and proliferation that are found in vivo. Here, we propose to use UHMWPE as a material of the cellular matrix, the ultra-high molecular weight polyethylene. UHMWP is a bioinert substance, wich allows forming a system of open connected pores needed to provide cellular life conditions with supply of nutrients and oxygen as well as the removal of waste products, the possibility of intercellular communication, etc. As a result, the use of UHMWPE as a cellular matrix will allow to study the processes occurring in cells in the 3D environment.Π Π°Π±ΠΎΡΠ° ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π° Π°Π½Π°Π»ΠΈΠ·Ρ ΡΠ²ΠΎΠΉΡΡΠ² ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΡΠ²Π΅ΡΡ
Π²ΡΡΠΎΠΊΠΎΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ»ΠΈΡΡΠΈΠ»Π΅Π½Π° (Π‘ΠΠΠΠ) Ρ ΠΏΠΎΡΠΈΡΡΠΎΠΉ ΠΈΠ»ΠΈ ΡΡΠ΅ΠΈΡΡΠΎΠΉ 3D-ΡΡΡΡΠΊΡΡΡΠΎΠΉ, ΠΊΠΎΡΠΎΡΡΠΉ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΡΡΡ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΡΠΈΠΊΡΠ° β ΠΊΠ°ΡΠΊΠ°ΡΠ° Π΄Π»Ρ Π²ΡΡΠ°ΡΠΈΠ²Π°Π½ΠΈΡ ΠΊΡΠ»ΡΡΡΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ. Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΡΠ°ΠΊΠΎΠ³ΠΎ ΠΊΠ°ΡΠΊΠ°ΡΠ° ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°Π΅Ρ ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΠΊΡΠ»ΡΡΡΡΡ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
, ΠΏΡΠΈΠ±Π»ΠΈΠΆΠ΅Π½Π½ΡΡ
ΠΊ ΡΠ΅ΠΌ, ΠΊΠΎΡΠΎΡΡΠ΅ ΡΡΡΠ΅ΡΡΠ²ΡΡΡ Π² ΠΆΠΈΠ²ΠΎΠΌ ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠ΅. ΠΠ°ΠΊ ΠΏΡΠ°Π²ΠΈΠ»ΠΎ, ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ in vitro ΠΏΡΠΎΠ²ΠΎΠ΄ΡΡ Π² 2D-ΡΠΎΡΠΌΠ°ΡΠ΅, ΠΊΠΎΡΠΎΡΡΠΉ ΠΏΠΎ ΡΠ²ΠΎΠ΅ΠΉ ΠΏΡΠΈΡΠΎΠ΄Π΅ ΠΎΠ³ΡΠ°Π½ΠΈΡΠΈΠ²Π°Π΅Ρ ΠΌΠ΅ΠΆΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠ΅ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ, ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡ, Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΡ, Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΡ, ΡΠΈΠ³Π½Π°Π»ΡΠ½ΡΠ΅ ΠΎΡΠ²Π΅ΡΡ, ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π³Π΅Π½ΠΎΠ² ΠΈ ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΡ, Π½Π°Π±Π»ΡΠ΄Π°Π΅ΠΌΡΠ΅ in vivo. Π ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΡΠΈΠΊΡΠ° ΠΏΡΠ΅Π΄Π»Π°Π³Π°Π΅ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡ Π±ΠΈΠΎΠΈΠ½Π΅ΡΡΠ½ΡΠΉ ΡΠ²Π΅ΡΡ
Π²ΡΡΠΎΠΊΠΎΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΠΉ ΠΏΠΎΠ»ΠΈΡΡΠΈΠ»Π΅Π½ (Π‘ΠΠΠΠ), ΠΊΠΎΡΠΎΡΡΠΉ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°ΡΡ ΡΠΈΡΡΠ΅ΠΌΡ ΠΎΡΠΊΡΡΡΡΡ
ΡΠ²ΡΠ·Π°Π½Π½ΡΡ
ΠΏΠΎΡ Ρ ΡΠ΅Π»ΡΡ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΡ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΠΆΠΈΠ·Π½Π΅Π΄Π΅ΡΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ β βΠΏΠΎΠ΄Π²ΠΎΠ΄β ΠΏΠΈΡΠ°Π½ΠΈΡ ΠΈ ΠΊΠΈΡΠ»ΠΎΡΠΎΠ΄Π°, ΡΠ΄Π°Π»Π΅Π½ΠΈΠ΅ ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ² ΠΆΠΈΠ·Π½Π΅Π΄Π΅ΡΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ, Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ ΠΎΡΡΡΠ΅ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΌΠ΅ΠΆΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ
ΡΠ²ΡΠ·Π΅ΠΉ ΠΈ Ρ.Π΄. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ Π‘ΠΠΠΠ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΡΠΈΠΊΡΠ° ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ ΠΈΠ·ΡΡΠΈΡΡ ΠΏΡΠΎΡΠ΅ΡΡΡ, ΠΏΡΠΎΡΠ΅ΠΊΠ°ΡΡΠΈΠ΅ Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
3D-ΡΡΠ΅Π΄Ρ
Justification and calculation of design features of drum-type hydroponics
The purpose of the article is to evaluate the design features of rotary hydroponics and then obtain a method for calculating the main technical characteristics. Drum (rotary) hydroponics is a promising method of growing on artificial media. The planting surface in this method is located on the inner cylindrical surface of the rotor rotating around the lamp. The design of the rotary hydroponics has a number of advantages such as: smaller installation area due to planting in the cylinder area; energy savings due to rational use of the light source; liquid saving for the formation of a nutrient solution due to the alternate immersion of the roots in a more compact bath. In this paper, a number of theoretical aspects for the calculation of drum (rotary) hydroponic machines is considered to ensure the highest productivity. As a result, a method for calculating the following characteristics was derived: determination of the required radius of the rotor depending on plant height; number of planting spots with a known radius and width of the rotor; minimum amount of necessary nutrient solution; electricity consumed when using LED lamps